Indications for Angiomax (Bivalirudin)
Angiomax (bivalirudin) is indicated as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI), including those with unstable angina, non-ST-elevation myocardial infarction (NSTEMI), ST-elevation myocardial infarction (STEMI), and patients with or at risk of heparin-induced thrombocytopenia (HIT). 1
Primary FDA-Approved Indications
Based on guideline evidence, bivalirudin has Class I, Level of Evidence B recommendation for use during PCI 1. The specific clinical scenarios include:
1. Acute Coronary Syndromes with PCI
- Unstable angina/NSTEMI: Bivalirudin is approved for anticoagulation during PCI in these patients, with or without provisional glycoprotein IIb/IIIa inhibitor use 1
- STEMI: Recommended for primary PCI in ST-elevation myocardial infarction 2
2. Heparin-Induced Thrombocytopenia
For patients with HIT, bivalirudin or argatroban should replace unfractionated heparin 1. This represents a critical indication where bivalirudin serves as a direct thrombin inhibitor alternative when heparin is contraindicated.
3. Elective PCI
Bivalirudin is indicated for percutaneous transluminal coronary angioplasty (balloon angioplasty) and contemporary PCI procedures 1
Dosing Strategy
The standard regimen involves:
- Bolus: 0.75 mg/kg IV
- Infusion: 1.75 mg/kg/h during the procedure
- Post-PCI: Optional reduced infusion of 0.25 mg/kg/h for 4-12 hours as clinically necessary 2
Key Clinical Considerations
Bleeding vs. Thrombosis Trade-off
Bivalirudin consistently reduces major bleeding by 40-50% compared to heparin plus routine glycoprotein IIb/IIIa inhibitors, but increases acute stent thrombosis risk by approximately 5-fold 2. This trade-off is critical:
- The bleeding benefit persists regardless of vascular access site (radial vs. femoral) 2
- The increased stent thrombosis risk relates to bivalirudin's short 25-minute half-life, leaving minimal antithrombin activity 2 hours post-PCI 2
- Extended post-PCI infusion (4 hours at reduced dose) may mitigate thrombosis risk 2, 3
Optimal Use Strategy
The lower bleeding rates associated with bivalirudin are mitigated when used concomitantly with a glycoprotein IIb/IIIa inhibitor 1. Therefore:
- Use bivalirudin as monotherapy with provisional (not routine) GP IIb/IIIa inhibitor strategy 1
- Reserve GP IIb/IIIa inhibitors for bailout situations during PCI
- Ensure adequate P2Y12 inhibitor loading before or during PCI to reduce early thrombotic events 2
Important Caveats
When NOT to Use Bivalirudin
- Do not use if concomitant routine GP IIb/IIIa inhibitor is planned - this negates the bleeding benefit while maintaining costs 1
- Consider alternative anticoagulation if extended post-procedural antithrombin coverage is needed beyond 4-12 hours
Special Populations
- Renal impairment: Bivalirudin undergoes predominant proteolytic elimination (not organ-dependent), making it advantageous in renal dysfunction 4
- Pediatric patients: Limited data exists; dosing extrapolated from adult studies 5
Monitoring
Activated clotting time (ACT) is prolonged by bivalirudin but ACT levels do not correlate with clinical efficacy 6. Target ACT is not a reliable endpoint for dose adjustment.
Clinical Bottom Line
Bivalirudin should be the preferred anticoagulant over unfractionated heparin plus routine GP IIb/IIIa inhibitors in patients undergoing PCI when bleeding risk reduction is prioritized 1. The consistent 40-50% reduction in major bleeding outweighs the small increase in acute stent thrombosis when modern antiplatelet therapy is used and post-PCI infusion is considered 2, 3. For patients with HIT, bivalirudin is a mandatory alternative to heparin 1.